That’s fine. Thank you very much. We just wanted to know that the submission plans were aligned with a potential regulatory opinion in

Thanks, again.

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Calle Campezo 1 • Edificio 8 • E-28022 Madrid • España/Spain

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addressee. If you are not the addressee, we ask you to notify to the sender, do not pass its content and delete the original.

De: [Redacted]@moderntx.com>
Enviado el: viernes, 7 de agosto de 2020 6:31
Para: [Redacted]@aemps.es>; [Redacted]@modernxt.com; [Redacted]@ec.europa.eu
CC: [Redacted]@modernxt.com>; [Redacted]@regeringskansliet.se; [Redacted]@modernxt.com; [Redacted]@ec.europa.eu
Asunto: RE: Presentation of new data concerning mRNA1273

Dear All,

Our aim is to discuss
I hope this helps and please let me know if you have any further questions.

Regards,

From: [Redacted] @aemps.es>
Sent: Thursday, August 6, 2020 3:58 AM
To: [Redacted] @modernatx.com>; [Redacted] @modernatx.com>; [Redacted] @ec.europa.eu
Cc: [Redacted] @modernatx.com>; [Redacted] @moderna.eu>

Subject: RE: Presentation of new data concerning mRNA1273

Dear all,

I was wondering if anyone has any insight on this?

Best regards,

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Calle Campezo 1 • Edificio 8 • E-28022 Madrid • España/Spain

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addressee. If you are not the addressee, we ask you to notify to the sender, do not pass its content and delete the original.

De: [Redacted] @modernatx.com>
Enviado el: domingo, 2 de agosto de 2020 18:23
Para: [Redacted] @modernatx.com>; [Redacted] @ec.europa.eu
CC: [Redacted] @modernatx.com>; [Redacted] @regeringskanalit.se; [Redacted] @aemp.es>

Asunto: RE: Presentation of new data concerning mRNA1273

Dear [Redacted]/All,
I hope this helps in providing you with an overview and please feel free to reach out to me if you’d like any additional information.

with best regards,

modernatx.com

-----Original Message-----
From: @modernatx.com
Sent: Wednesday, July 29, 2020 2:53 PM
To: @ec.europa.eu
Cc: @modernatx.com; @modernatx.com; @aemps.es; @modernatx.com; @ec.europa.eu; @modernatx.com
Subject: Re: Presentation of new data concerning mRNA1273

Hi
Thank you for this confirmation.
I have copied so that he can summarize the status of discussions with the EMA.

Regards

On 7/29/20, 2:47 PM, @ec.europa.eu wrote:

Hi

Just to confirm that I have circulated this letter.

One issue which I realised we didn't get round to discussing during our meeting, but which could be quite important operationally, was your plans re regulatory filing with EMA. We'd welcome some more info from you on this - you can either send us something via email or we can discuss next week.

Regards

-----Original Message-----
From: @modernatx.com
Sent: Wednesday, July 29, 2020 3:53 AM
To: (SG) @ec.europa.eu
Cc: @modernatx.com; @regeringskansliet.se; @aemps.es; @modernatx.com; [SANTE] @ec.europa.eu
Subject: Re: Presentation of new data concerning mRNA1273

Good morning,

Please find attached a letter from Moderna, inviting member states to participate in a scientific data exchange with Moderna.

Please be so kind as to forward the letter extending the invitation.

Thanking you in advance

P. Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of,
or taking of any action in reliance upon, of any such information by persons or entities other
than the intended addressee(s) is prohibited. If you have received this message in error and are
not the intended addressee, please notify the sender immediately and delete this message and
any attachments from your system without reading or disclosing them. If you are not the
intended addressee, be advised that any use of the information in this message and any
attachment is prohibited and may be unlawful, and you must not copy this message or
attachment or disclose the contents to any other person.

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y
va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo
indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and
exclusively for the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not
pass its content and delete the original.

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y
va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo
indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and
exclusively for the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not
pass its content and delete the original.